2026-04-02 from globalnews.ca
A recently released study suggests that fluvoxamine, a low?cost and widely available antidepressant, “significantly improved fatigue and quality of life among adults with long COVID.”
The study was co?led by researchers at McMaster University, alongside those in Brazil and the United States, conducting a clinical trial with 399 adults with fatigue persisting 90 or more days after confirmed SARS-CoV-2 infection.
The results found that fluvoxamine “showed a significant reduction in fatigue compared with placebo at day 60,” alongside “improv[ing] quality-of-life scores with high posterior probability.”
Read more here